Toktam Sahranavard, Shima Mehrabadi, Ghazaleh Pourali, Mina Maftooh, Hamed Akbarzade, Seyed Mahdi Hassanian, Majid Ghayour Mobarhan, Gordon A Ferns, Majid Khazaei and Amir Avan* Pages 1 - 11 ( 11 )
The application of the CRISPR-associated nuclease 9 (Cas9) system in tumor studies has led to the discovery of several new treatment strategies for colorectal cancer (CRC), including the recognition of novel target genes, the construction of animal mass models, and the identification of genes related to chemotherapy resistance. CRISPR/Cas9 can be applied to genome therapy for CRC, particularly regarding molecular-targeted medicines and suppressors. This review summarizes some aspects of using CRISPR/- Cas9 in treating CRC. Further in-depth and systematic research is required to fully realize the potential of CRISPR/Cas9 in CRC treatment and integrate it into clinical practice.
CRISPR-Cas systems, colorectal neoplasms, gene editing, therapeutics, precision medicine.